Treating Center of Spinal Cord Injury, Chinese PLA Chengdu Army Kunming General Hospital
Kunming, Yunnan, 650032, China
NCT Number: NCT01471613
The trial is to investigate the safety and efficacy of oral lithium, intraspinal umbilical cord blood mononuclear cell transplant, and the combination in the treatment of acute and subacute spinal cord injury
Looking for future studies?
Notify Me18 year–65 year
All sexes
Interventional
Phase 1 / Phase 2
Kunming, Yunnan, 650032, China
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Conventional treatment includes surgeries such as laminectomy, spinal decompression etc. and the medicine generally adapted to treat spinal cord injury
250mg/tablet, administrated orally for 6 weeks.
Cord blood mononuclear cell, 6.4 million viable cells, are transplanted into spinal cord at upper and lower edges of the injured site
Placebo tablet, orally administration of placebo for 6 weeks
Time frame: Week 0, 1, 2, 6, 14, 24 and 48
Time frame: Week 2, 6, 14, 24, 48
Walking Index of Spinal Cord Injury (WISCI)
Time frame: Week 2, 6, 14, 24, 48
Spinal Cord Injury Measure (SCIM) Score
Time frame: Week 2, 6, 14, 24, 48
Kunming locomotor scales
Time frame: Week 2, 6, 14, 24, 48
Modified Ashworth Scale
Time frame: Week 2, 6, 14, 24, 48
Numerical rating scales
China Spinal Cord Injury Network
Network
Safety and Effect of Lithium, Umbilical Cord Blood Cells and the Combination in the Treatment of Acute and Sub-acute Spinal Cord Injury : a Randomized, Double-Blinded Placebo-Controlled Clinical Trial
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07507331
Autoimmune Diseases, Autoimmune Diseases of the Nervous System
Ankara, Çankaya, Turkey (Türkiye)
View Trial DetailsNCT05433064
Central Nervous System Diseases, Nervous System Diseases
Hualien City, Taiwan
View Trial DetailsNCT07717606
Central Nervous System Diseases, Conus Medullaris Injury
Istanbul, Turkey (Türkiye)
View Trial DetailsNCT07706517
Brain Damage, Chronic, Brain Diseases
Saint-Etienne, France
View Trial Details